PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7834629-0 1995 Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cisplatin 53-81 interleukin 6 Homo sapiens 94-107 7553641-0 1995 Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cisplatin 52-80 interleukin 6 Homo sapiens 11-24 7553641-10 1995 CDDP treatment of tumor cells down-regulated IL-6 mRNA expression and IL-6 secretion. Cisplatin 0-4 interleukin 6 Homo sapiens 45-49 7553641-10 1995 CDDP treatment of tumor cells down-regulated IL-6 mRNA expression and IL-6 secretion. Cisplatin 0-4 interleukin 6 Homo sapiens 70-74 7834629-16 1995 This study demonstrates that treatment of RCC cells with CDDP in combination with anti-IL-6 mAb or anti-IL-6R mAb can overcome their CDDP-resistance and that the down-regulation of glutathione S-transferase pi expression by anti-IL-6 mAb or anti-IL-6R mAb might play a role in the enhanced cytotoxicity obtained. Cisplatin 57-61 interleukin 6 Homo sapiens 87-91 7834629-16 1995 This study demonstrates that treatment of RCC cells with CDDP in combination with anti-IL-6 mAb or anti-IL-6R mAb can overcome their CDDP-resistance and that the down-regulation of glutathione S-transferase pi expression by anti-IL-6 mAb or anti-IL-6R mAb might play a role in the enhanced cytotoxicity obtained. Cisplatin 133-137 interleukin 6 Homo sapiens 87-91 7834629-16 1995 This study demonstrates that treatment of RCC cells with CDDP in combination with anti-IL-6 mAb or anti-IL-6R mAb can overcome their CDDP-resistance and that the down-regulation of glutathione S-transferase pi expression by anti-IL-6 mAb or anti-IL-6R mAb might play a role in the enhanced cytotoxicity obtained. Cisplatin 133-137 interleukin 6 Homo sapiens 104-108 7834629-7 1995 Treatment of Caki-1 cells with anti-IL-6 mAb or anti-IL-6R mAb in combination with cis-diamminedichloroplatinum(II) (CDDP) or mitomycin C overcame their resistance to CDDP or mitomycin C. Cisplatin 167-171 interleukin 6 Homo sapiens 36-40 35533545-9 2022 The results suggested that ameliorating cisplatin-induced AKI actions of 9b was involved in downregulation of TNF-alpha, IL-1beta, IL-6, and MCP-1, inhibition of NF-kB activation, and reduction of GRPR and oxidative stress level. Cisplatin 40-49 interleukin 6 Homo sapiens 131-135 34132362-0 2021 miR-375/Yes-associated protein axis regulates IL-6 and TGF-beta expression, which is involved in the cisplatin-induced resistance of liver cancer cells. Cisplatin 101-110 interleukin 6 Homo sapiens 46-50 34132362-8 2021 In conclusion, the findings of the present study suggested that the miR-375/YAP axis may regulate the expression levels of IL-6 and TGF-beta, which may subsequently be involved in the CDDP resistance of LC cells. Cisplatin 184-188 interleukin 6 Homo sapiens 123-127 34262937-13 2021 In addition, silencing STUB1 increased the apoptosis of HK-2 cells and the proinflammatory cytokine production of IL6, TNFalpha, and IL1beta induced by cisplatin. Cisplatin 152-161 interleukin 6 Homo sapiens 114-117 34139285-0 2021 Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cisplatin 152-161 interleukin 6 Homo sapiens 94-98 34375503-8 2021 Using the STAT3 inhibitor stattic to block the IL-6/STAT3 signaling pathway strongly increased the sensitivity of ZIPK-expressed cells to cisplatin. Cisplatin 138-147 interleukin 6 Homo sapiens 47-51 34375503-9 2021 In conclusion, ZIPK may play a role in cisplatin resistance through activation of the IL-6/ STAT3 signaling pathway. Cisplatin 39-48 interleukin 6 Homo sapiens 86-90 34094941-0 2021 lncRNA MIAT/HMGB1 Axis Is Involved in Cisplatin Resistance via Regulating IL6-Mediated Activation of the JAK2/STAT3 Pathway in Nasopharyngeal Carcinoma. Cisplatin 38-47 interleukin 6 Homo sapiens 74-77 34094941-8 2021 We find that the deficiency of the lncRNA MIAT/HMGB1 axis, inhibition of JAK2/STAT3, or neutralization of IL6 by antibodies significantly re-sensitizes resistant NPC cells to cisplatin in resistant NPC cells. Cisplatin 175-184 interleukin 6 Homo sapiens 106-109 35624727-6 2022 In a dose-dependent manner, concomitant administration of kinetin with cisplatin significantly restored testicular oxidative stress parameters, corrected the distorted sperm quality parameters and histopathological changes, enhanced levels of serum testosterone and testicular StAR protein expression, as well as reduced the up-regulation of testicular TNF-alpha, IL-1beta, Il-6, and caspase-3, caused by cisplatin. Cisplatin 71-80 interleukin 6 Homo sapiens 374-378 35356749-0 2022 circRNA_101277 Influences Cisplatin Resistance of Colorectal Cancer Cells by Modulating the miR-370/IL-6 Axis. Cisplatin 26-35 interleukin 6 Homo sapiens 100-104 35433741-11 2022 Meanwhile, the enhanced protein levels of Bax, cleaved caspase-3/caspase-3 ratio, levels of Pp-65/p-65, levels of IL-6, and the production of ROS induced by cisplatin were significantly attenuated by ISL treatment. Cisplatin 157-166 interleukin 6 Homo sapiens 114-118 32127934-0 2020 Mesenchymal stem/stromal cells-derived IL-6 promotes nasopharyngeal carcinoma growth and resistance to cisplatin via upregulating CD73 expression. Cisplatin 103-112 interleukin 6 Homo sapiens 39-43 35356749-11 2022 At a mechanistic level, circRNA_101277 was found to function by sequestering miR-370, thereby upregulating the miR-370 target gene IL-6 and promoting cisplatin resistance via this miR-370/IL-6 axis. Cisplatin 150-159 interleukin 6 Homo sapiens 188-192 35356749-12 2022 Conclusion: In summary, our data highlight circRNA_101277 as a novel driver of CRC cell cisplatin resistance that functions by sequestering miR-370 and thereby enhancing IL-6 expression. Cisplatin 88-97 interleukin 6 Homo sapiens 170-174 33727094-9 2021 The interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha) release of SGCs increased after cisplatin exposure as measured using ELISA, and interleukin-1beta (IL-1beta) decreased. Cisplatin 100-109 interleukin 6 Homo sapiens 4-17 33727094-9 2021 The interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha) release of SGCs increased after cisplatin exposure as measured using ELISA, and interleukin-1beta (IL-1beta) decreased. Cisplatin 100-109 interleukin 6 Homo sapiens 19-23 32930970-9 2021 RESULTS: We found that IL-6 triggered stem cell-like properties in cisplatin-treated gastric cancer cells and activated STAT3, which in turn transcriptionally regulated SNHG3 expression. Cisplatin 67-76 interleukin 6 Homo sapiens 23-27 32434541-0 2020 Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner. Cisplatin 0-9 interleukin 6 Homo sapiens 28-47 32434541-11 2020 Cisplatin but not erlotinib increased both IL-6 and IL-8 secretion and only IL-6 increased cellular migration and proliferation. Cisplatin 0-9 interleukin 6 Homo sapiens 43-47 33813381-9 2021 IL-6 production was increased following treatment with CDDP, but treatment with EPA decreased IL-6 levels. Cisplatin 55-59 interleukin 6 Homo sapiens 0-4 33345849-8 2021 Proliferation assay and apoptosis assay were applied and proved that IL-6 enhances the chemoresistance of OvCa cells against cisplatin through the upregulation of HIF-1alpha via the STAT3 signaling in vitro. Cisplatin 125-134 interleukin 6 Homo sapiens 69-73 33345849-9 2021 The In vivo studies confirmed the effect of IL-6 in increasing the chemoresistance of OvCa cells against cisplatin through the IL-6/STAT3/HIF-1alpha loop in the animal models. Cisplatin 105-114 interleukin 6 Homo sapiens 44-48 32875568-5 2021 Our data demonstrated that tumor-produced IL-6 conferred resistance to cisplatin and therapeutic vaccination. Cisplatin 71-80 interleukin 6 Homo sapiens 42-46 31983246-6 2020 In vitro studies revealed serum levels of BUN, creatinine, CK and pro-inflammatory cytokines like TNF-alpha, IL-6, and MRP-1 to be elevated in the cisplatin-treated group while reducing glomerular filtration rate. Cisplatin 147-156 interleukin 6 Homo sapiens 109-113 29767234-6 2018 Furthermore, the combination of miR-125a-5p and cisplatin markedly inactivated the STAT3 signaling pathway; however, interleukin (IL)-6, a widely reported activator of the STAT3 signaling pathway, reversed the suppressive effects of miR-125a-5p/cisplatin in ESCC cells on the activation of the STAT3 signaling pathway. Cisplatin 245-254 interleukin 6 Homo sapiens 117-135 31497913-6 2020 We also found that quercetin can strongly reduce the concentration of serum creatinine, BUN, IL-1beta, IL-6, and TNF-alpha in cisplatin-induced AKI model. Cisplatin 126-135 interleukin 6 Homo sapiens 103-107 31570278-6 2019 Additionally, evidence was provided that TET2 regulated interleukin-6 levels in the tumor microenvironment through histone acetylation and therefore served an important role in the development of cisplatin resistance in GC cells. Cisplatin 196-205 interleukin 6 Homo sapiens 56-69 30670152-4 2019 We found that endothelial IL-6 levels were significantly higher in response to cisplatin treatment, whereas levels of IL-6 upon cisplatin exposure remained unchanged in MDA-MB-231 breast cancer cells. Cisplatin 79-88 interleukin 6 Homo sapiens 26-30 30670152-4 2019 We found that endothelial IL-6 levels were significantly higher in response to cisplatin treatment, whereas levels of IL-6 upon cisplatin exposure remained unchanged in MDA-MB-231 breast cancer cells. Cisplatin 128-137 interleukin 6 Homo sapiens 118-122 30670152-5 2019 We additionally found an inverse correlation between IL-6 and miR-125a/let-7e expression levels in cisplatin treated ECs. Cisplatin 99-108 interleukin 6 Homo sapiens 53-57 29767234-7 2018 Of note, we found that IL-6 markedly reversed the altered cell phenotype mediated by the combination of miR-125a-5p and cisplatin in ESCC cells. Cisplatin 120-129 interleukin 6 Homo sapiens 23-27 29545331-5 2018 First, we found a significant stromal overexpression of IL6 in patient samples that received cisplatin-based treatment, which was further validated in purified fibroblasts challenged with cisplatin. Cisplatin 93-102 interleukin 6 Homo sapiens 56-59 29545331-5 2018 First, we found a significant stromal overexpression of IL6 in patient samples that received cisplatin-based treatment, which was further validated in purified fibroblasts challenged with cisplatin. Cisplatin 188-197 interleukin 6 Homo sapiens 56-59 29059160-6 2018 In clinical samples, ESCC patients with high expression of CXCR7 and IL6 presented a significantly worse overall survival and progression-free survival upon receiving cisplatin after operation. Cisplatin 167-176 interleukin 6 Homo sapiens 69-72 29761938-10 2018 PD-L1 and IL-6 in the established cisplatin-resistant HNSCC cells were shown significantly higher (P < .05). Cisplatin 34-43 interleukin 6 Homo sapiens 10-14 29731768-0 2018 TIMP3 Overexpression Improves the Sensitivity of Osteosarcoma to Cisplatin by Reducing IL-6 Production. Cisplatin 65-74 interleukin 6 Homo sapiens 87-91 29731768-16 2018 In conclusion, cisplatin sensitivity correlated positively with TIMP3 expression, which is regulated by the IL-6/TIMP3/caspase pathway. Cisplatin 15-24 interleukin 6 Homo sapiens 108-112 29844821-0 2018 Tumor-derived mesenchymal-stem-cell-secreted IL-6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer. Cisplatin 73-82 interleukin 6 Homo sapiens 45-49 29844821-8 2018 Taken together, the findings of the present study indicated that BC-MSCs decreased the level of cisplatin-induced apoptosis in MCF-7 cells by activating the IL-6/STAT3 pathway in cancer cells. Cisplatin 96-105 interleukin 6 Homo sapiens 157-161 29861860-7 2018 Gene set enrichment analysis and iPathway analysis identified signaling pathways with major implications to the pathobiology of cancer (e.g. TNFalpha, IFN, IL6/STAT, NF-kappaB) that are enriched in cisplatin-resistant ALDHhighCD44high cells, when compared to control cells. Cisplatin 198-207 interleukin 6 Homo sapiens 156-159 29761938-13 2018 Besides, the increase of IL-6 and PD-L1 in cisplatin-resistant HNSCC cells was abolished in vitro by LfcinB (P < .05). Cisplatin 43-52 interleukin 6 Homo sapiens 25-29 28473707-7 2017 Among the strongest changes was also induction of IL6 in resistant cells and the expression was further increased in response to cisplatin. Cisplatin 129-138 interleukin 6 Homo sapiens 50-53 28356286-5 2017 With early treatment, cisplatin nephrotoxicity was attenuated as evidenced by decreased blood urea nitrogen (BUN) and reduced apoptosis and tubular injury scores on day 3 Early treatment resulted in downregulation of intrarenal monocyte chemotactic protein-1 and IL-6 expression and upregulation of IL-10 and VEGF expression. Cisplatin 22-31 interleukin 6 Homo sapiens 263-267 28878571-0 2017 Ribonucleic acid interference knockdown of IL-6 enhances the efficacy of cisplatin in laryngeal cancer stem cells by down-regulating the IL-6/STAT3/HIF1 pathway. Cisplatin 73-82 interleukin 6 Homo sapiens 43-47 28878571-0 2017 Ribonucleic acid interference knockdown of IL-6 enhances the efficacy of cisplatin in laryngeal cancer stem cells by down-regulating the IL-6/STAT3/HIF1 pathway. Cisplatin 73-82 interleukin 6 Homo sapiens 137-141 28878571-2 2017 This study aimed to investigate whether interleukin-6 (IL-6) knockdown may enhance the efficacy of cisplatin in laryngeal cancer stem cells (CSC) and the potential involvement of the signal transducer and activator of transcription 3 (STAT3) and hypoxia-inducible factor 1 (HIF1) in this effect. Cisplatin 99-108 interleukin 6 Homo sapiens 40-53 28878571-2 2017 This study aimed to investigate whether interleukin-6 (IL-6) knockdown may enhance the efficacy of cisplatin in laryngeal cancer stem cells (CSC) and the potential involvement of the signal transducer and activator of transcription 3 (STAT3) and hypoxia-inducible factor 1 (HIF1) in this effect. Cisplatin 99-108 interleukin 6 Homo sapiens 55-59 28878571-13 2017 Results from the xenograft study showed that the combination of IL-6 knockdown and cisplatin further inhibited the growth of xenografts as compared with that obtained in the cisplatin-injected group alone. Cisplatin 174-183 interleukin 6 Homo sapiens 64-68 28878571-15 2017 IL-6, STAT3 and HIF1 immunoreactive cell counts were further reduced in tissue where IL-6 knockdown was combined with cisplatin treatment as compared with tissue receiving cisplatin alone. Cisplatin 118-127 interleukin 6 Homo sapiens 0-4 28878571-15 2017 IL-6, STAT3 and HIF1 immunoreactive cell counts were further reduced in tissue where IL-6 knockdown was combined with cisplatin treatment as compared with tissue receiving cisplatin alone. Cisplatin 172-181 interleukin 6 Homo sapiens 85-89 28878571-16 2017 CONCLUSIONS: IL-6 knockdown can increase chemo-drug efficacy of cisplatin, inhibit tumor growth and reduce the potential for tumor recurrence and metastasis in laryngeal cancer. Cisplatin 64-73 interleukin 6 Homo sapiens 13-17 28388577-3 2017 Repression of miR-204 was required for IL-6-induced cisplatin (cDDP) resistance. Cisplatin 52-61 interleukin 6 Homo sapiens 39-43 28388577-3 2017 Repression of miR-204 was required for IL-6-induced cisplatin (cDDP) resistance. Cisplatin 63-67 interleukin 6 Homo sapiens 39-43 28182789-7 2017 Renal levels of TNF-alpha and IL-6, two important inflammatory cytokines, were also upregulated by cisplatin. Cisplatin 99-108 interleukin 6 Homo sapiens 30-34 28454469-12 2017 Furthermore, the baicalein-cisplatin combination suppressed the secretion of interleukin-6, and baicalein and the combination of baicalein cisplatin decreased the secretion of tumor necrosis factor-alpha of A549 cells. Cisplatin 27-36 interleukin 6 Homo sapiens 77-90 27824145-6 2016 For the molecular mechanisms, CDDP alone increased the cancer stem cell (CSC)-like properties in gastric cancer cells via activating the interleukin-6 (IL-6)/IL-6 receptor (IL-6R)/signal transducer and activator of transcription 3 (STAT3) signaling. Cisplatin 30-34 interleukin 6 Homo sapiens 137-150 27824145-6 2016 For the molecular mechanisms, CDDP alone increased the cancer stem cell (CSC)-like properties in gastric cancer cells via activating the interleukin-6 (IL-6)/IL-6 receptor (IL-6R)/signal transducer and activator of transcription 3 (STAT3) signaling. Cisplatin 30-34 interleukin 6 Homo sapiens 152-156 27824145-6 2016 For the molecular mechanisms, CDDP alone increased the cancer stem cell (CSC)-like properties in gastric cancer cells via activating the interleukin-6 (IL-6)/IL-6 receptor (IL-6R)/signal transducer and activator of transcription 3 (STAT3) signaling. Cisplatin 30-34 interleukin 6 Homo sapiens 158-162 28978005-0 2017 Bazedoxifene enhances the anti-tumor effects of cisplatin and radiation treatment by blocking IL-6 signaling in head and neck cancer. Cisplatin 48-57 interleukin 6 Homo sapiens 94-98 27287412-7 2016 Cisplatin treatment increased expression of transforming growth factor-beta in cancer cells, and the conditioned media from cancer cells activated fibroblasts and increased their IL-6 production. Cisplatin 0-9 interleukin 6 Homo sapiens 179-183 27206315-10 2016 Indeed, treatment of OC cell lines with TNFalpha and IL6 induced a selective increase in the expression of TAP1 and multidrug resistance protein 1, whereas TAP1 silencing sensitized cells to cisplatin-induced apoptosis. Cisplatin 191-200 interleukin 6 Homo sapiens 53-56 27216197-8 2016 Unexpectedly, IL6-type cytokine signaling inducing STAT3 activation rendered cervical cancer cells significantly more susceptible to chemotherapeutic drugs, that is, cisplatin or etoposide. Cisplatin 166-175 interleukin 6 Homo sapiens 14-17 27009878-0 2016 Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer. Cisplatin 0-9 interleukin 6 Homo sapiens 92-105 27009878-3 2016 When A549CisR and H157CisR cells were treated with neutralizing IL-6 antibody, decreased cisplatin resistance was observed, whereas IL-6 treatment of parental cells resulted in increased cisplatin resistance. Cisplatin 89-98 interleukin 6 Homo sapiens 64-68 27009878-7 2016 Treatment of HIF inhibitor (FM19G11) abolished the upregulation of CSC markers and increased sphere formations in IL-6 expressing cells on cisplatin treatment. Cisplatin 139-148 interleukin 6 Homo sapiens 114-118 27009878-3 2016 When A549CisR and H157CisR cells were treated with neutralizing IL-6 antibody, decreased cisplatin resistance was observed, whereas IL-6 treatment of parental cells resulted in increased cisplatin resistance. Cisplatin 187-196 interleukin 6 Homo sapiens 132-136 27009878-8 2016 In all, IL-6-mediated HIF upregulation is important in increasing stemness during cisplatin resistance development, and we suggest that the strategies of inhibiting IL-6 signaling or its downstream HIF molecules can be used as future therapeutic approaches to target CSCs after cisplatin treatment for lung cancer. Cisplatin 82-91 interleukin 6 Homo sapiens 8-12 27009878-8 2016 In all, IL-6-mediated HIF upregulation is important in increasing stemness during cisplatin resistance development, and we suggest that the strategies of inhibiting IL-6 signaling or its downstream HIF molecules can be used as future therapeutic approaches to target CSCs after cisplatin treatment for lung cancer. Cisplatin 278-287 interleukin 6 Homo sapiens 8-12 27009878-5 2016 Hypoxia inducible factors (HIFs) were upregulated by IL-6 and responsible for the increased CSC stemness on cisplatin treatment. Cisplatin 108-117 interleukin 6 Homo sapiens 53-57 26313152-0 2015 IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. Cisplatin 30-39 interleukin 6 Homo sapiens 0-4 26597704-3 2016 In this study, we found that the low-affinity leukotriene B4 receptor-2 (BLT2) and its ligand leukotriene B4 were highly up-regulated in cisplatin-resistant SK-OV-3 ovarian cancer cells and play critical roles in mediating the chemoresistance through the activation of signal transducer and activator of transcription-3 (STAT-3) and the subsequent up-regulation of interleukin-6 (IL-6). Cisplatin 137-146 interleukin 6 Homo sapiens 365-378 26597704-3 2016 In this study, we found that the low-affinity leukotriene B4 receptor-2 (BLT2) and its ligand leukotriene B4 were highly up-regulated in cisplatin-resistant SK-OV-3 ovarian cancer cells and play critical roles in mediating the chemoresistance through the activation of signal transducer and activator of transcription-3 (STAT-3) and the subsequent up-regulation of interleukin-6 (IL-6). Cisplatin 137-146 interleukin 6 Homo sapiens 380-384 26439246-7 2016 A single dose of cisplatin (7.5 mg/kg) resulted in significant increase in serum creatinine, blood urea nitrogen, NF-kB, TNF-alpha and IL-6 levels along with decrease in albumin and IL-10 levels. Cisplatin 17-26 interleukin 6 Homo sapiens 135-139 27108527-0 2016 Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma. Cisplatin 82-91 interleukin 6 Homo sapiens 10-23 27108527-3 2016 Similar tendency was observed in platinum treated patients, suggesting an IL-6 associated cisplatin resistance. Cisplatin 90-99 interleukin 6 Homo sapiens 74-78 27108527-4 2016 IL-6 increase was also found in two in-house acquired cisplatin-resistant HNSCC cell lines (both basaloid and conventional squamous cell carcinoma) by using microarray analysis. Cisplatin 54-63 interleukin 6 Homo sapiens 0-4 27108527-5 2016 However, although the in-house acquired cisplatin-resistant cell lines had higher basal and markedly increased cisplatin-induced IL-6 expression, IL-6 did not mediate the cisplatin resistance as neither exogenous IL-6 nor IL-6R/gp130 inhibitors affected cisplatin sensitivity. Cisplatin 40-49 interleukin 6 Homo sapiens 129-133 27108527-5 2016 However, although the in-house acquired cisplatin-resistant cell lines had higher basal and markedly increased cisplatin-induced IL-6 expression, IL-6 did not mediate the cisplatin resistance as neither exogenous IL-6 nor IL-6R/gp130 inhibitors affected cisplatin sensitivity. Cisplatin 111-120 interleukin 6 Homo sapiens 129-133 27108527-5 2016 However, although the in-house acquired cisplatin-resistant cell lines had higher basal and markedly increased cisplatin-induced IL-6 expression, IL-6 did not mediate the cisplatin resistance as neither exogenous IL-6 nor IL-6R/gp130 inhibitors affected cisplatin sensitivity. Cisplatin 111-120 interleukin 6 Homo sapiens 129-133 27108527-5 2016 However, although the in-house acquired cisplatin-resistant cell lines had higher basal and markedly increased cisplatin-induced IL-6 expression, IL-6 did not mediate the cisplatin resistance as neither exogenous IL-6 nor IL-6R/gp130 inhibitors affected cisplatin sensitivity. Cisplatin 111-120 interleukin 6 Homo sapiens 129-133 27108527-7 2016 Thus, high IL-6 expression correlated to poor prognosis and acquired cisplatin resistance, but it did not mediate cisplatin resistance in the HNSCC cell lines. Cisplatin 69-78 interleukin 6 Homo sapiens 11-15 26759169-8 2016 However, MSC pretreatment with cisplatin led to changes in phosphorylation profiles of many kinases and also increased secretion of IL-6 and IL-8 cytokines. Cisplatin 31-40 interleukin 6 Homo sapiens 132-136 26193055-4 2015 Erdosteine significantly suppressed the production of reactive nitrogen/oxygen species and pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6 in cisplatin-treated cells. Cisplatin 191-200 interleukin 6 Homo sapiens 183-187 26313152-2 2015 The potential implication of IL-6 signaling in the cisplatin resistance of NSCLC was explored by testing whether NSCLC cells with different levels of intracellular IL-6 show different responses to the cytotoxic treatment of cisplatin. Cisplatin 51-60 interleukin 6 Homo sapiens 29-33 26313152-3 2015 When the cisplatin cytotoxicity of the IL-6 knocked down human NSCLC cells (A549IL-6si and H157IL-6si) were compared with their corresponding scramble control cells (A549sc and H157sc), higher cisplatin cytotoxicity was found in IL-6 si cells than sc cells. Cisplatin 9-18 interleukin 6 Homo sapiens 39-43 26313152-10 2015 These results provide potential for combining cisplatin and inhibitors of IL-6 signaling or its downstream signaling pathway as a future therapeutic approach in preventing development of cisplatin resistant NSCLC tumors. Cisplatin 187-196 interleukin 6 Homo sapiens 74-78 25272046-0 2014 Long-term aerobic exercise protects against cisplatin-induced nephrotoxicity by modulating the expression of IL-6 and HO-1. Cisplatin 44-53 interleukin 6 Homo sapiens 109-113 25548514-0 2014 Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway. Cisplatin 42-51 interleukin 6 Homo sapiens 180-184 24286513-8 2014 Acetyl-L-carnitine-cisplatin also caused reduced levels of IL-6, IL-1beta and TNF-alpha, pro-inflammatory cytokines, induced by cisplatin. Cisplatin 19-28 interleukin 6 Homo sapiens 59-63 24988892-5 2014 Most importantly, lung cancer cells themselves upregulated IL-6 secretion by activating the p38/NF-kappaB pathway through treatment with cisplatin and camptothecin. Cisplatin 137-146 interleukin 6 Homo sapiens 59-63 24796665-4 2014 ALA pretreatment significantly reduced apoptotic cell death of the inner and outer hair cells in cisplatin-treated organ of Corti explants and attenuated ototoxicity via marked inhibition of the increase in the expression of IL-1beta and IL-6, the phosphorylation of ERK and p38, the degradation of IkappaBalpha, the increase in intracellular levels of ROS, and the activation of caspase-3 in cisplatin-treated HEI-OC1 cells. Cisplatin 97-106 interleukin 6 Homo sapiens 238-242 24286513-8 2014 Acetyl-L-carnitine-cisplatin also caused reduced levels of IL-6, IL-1beta and TNF-alpha, pro-inflammatory cytokines, induced by cisplatin. Cisplatin 128-137 interleukin 6 Homo sapiens 59-63 23749899-8 2013 Under treatment with low concentrations of 5-fluorouracil and cisplatin, all examined cell lines showed an increasing secretion of the cytokines IL-6 and G-CSF. Cisplatin 62-71 interleukin 6 Homo sapiens 145-149 24709421-8 2014 IL-6 potentiated cisplatin-induced orosphere formation generated when primary human HNSCC cells were sorted for ALDH(high)CD44(high) immediately after surgery and plated onto ultralow attachment plates. Cisplatin 17-26 interleukin 6 Homo sapiens 0-4 24709421-9 2014 IL-6-induced signal transducer and activator of transcription 3 (STAT3) phosphorylation (indicative of stemness) was unaffected by treatment with cisplatin in UM-SCC-22B cells, whereas IL-6-induced extracellular signal-regulated kinase (ERK) phosphorylation (indicative of differentiation processes) was partially inhibited by cisplatin. Cisplatin 327-336 interleukin 6 Homo sapiens 0-4 21273582-0 2011 Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Cisplatin 43-52 interleukin 6 Homo sapiens 18-31 23665025-6 2013 Interleukin-6 (IL-6) could induce STAT3 activation in cisplatin-sensitive ovarian cancer cells and led to protection against cisplatin. Cisplatin 54-63 interleukin 6 Homo sapiens 0-13 23665025-6 2013 Interleukin-6 (IL-6) could induce STAT3 activation in cisplatin-sensitive ovarian cancer cells and led to protection against cisplatin. Cisplatin 54-63 interleukin 6 Homo sapiens 15-19 23665025-6 2013 Interleukin-6 (IL-6) could induce STAT3 activation in cisplatin-sensitive ovarian cancer cells and led to protection against cisplatin. Cisplatin 125-134 interleukin 6 Homo sapiens 0-13 23665025-6 2013 Interleukin-6 (IL-6) could induce STAT3 activation in cisplatin-sensitive ovarian cancer cells and led to protection against cisplatin. Cisplatin 125-134 interleukin 6 Homo sapiens 15-19 22847808-12 2012 Let-7 modulates the chemosensitivity to cisplatin through the regulation of IL-6/STAT3 pathway in esophageal cancer. Cisplatin 40-49 interleukin 6 Homo sapiens 76-80 21148032-5 2011 Furthermore, cisplatin increased the interaction between TLR4 and its microbial ligand LPS, thereby upregulating the production of proinflammatory cytokines, such as TNF-alpha, IL-1beta, and IL-6, via NF-kappaB activation. Cisplatin 13-22 interleukin 6 Homo sapiens 191-195 23436796-4 2013 Treatment with cisplatin or carboplatin increased the potency of tumor cell lines to induce IL-10-producing M2 macrophages, which displayed increased levels of activated STAT3 due to tumor-produced IL-6 as well as decreased levels of activated STAT1 and STAT6 related to the PGE(2) production of tumor cells. Cisplatin 15-24 interleukin 6 Homo sapiens 198-202 23052480-7 2013 Our results revealed a highly significant increase in IL-6 and cIAP-2 mRNA and protein levels upon treatment with cisplatin. Cisplatin 114-123 interleukin 6 Homo sapiens 54-58 23052480-8 2013 WB analysis of cisplatin-treated cells exhibited decreased cIAP-2 expression level following anti-IL-6 Ab addition. Cisplatin 15-24 interleukin 6 Homo sapiens 98-102 23052480-10 2013 Finally, cytotoxicity assays showed sensitization to cisplatin following the addition of IL-6 and cIAP-2 inhibitors. Cisplatin 53-62 interleukin 6 Homo sapiens 89-93 23052480-11 2013 In conclusion, cisplatin treatment of ovarian carcinoma cells upregulates IL-6 and cIAP-2 levels while their inhibition significantly sensitizes them to cisplatin. Cisplatin 15-24 interleukin 6 Homo sapiens 74-78 23052480-12 2013 Here, we present cIAP-2 as a novel inducer of platinum resistance in ovarian carcinoma cells, and suggest an axis beginning with an encounter between cisplatin and these cells, mediated sequentially by IL-6 and cIAP-2, resulting in cisplatin resistance. Cisplatin 150-159 interleukin 6 Homo sapiens 202-206 23052480-12 2013 Here, we present cIAP-2 as a novel inducer of platinum resistance in ovarian carcinoma cells, and suggest an axis beginning with an encounter between cisplatin and these cells, mediated sequentially by IL-6 and cIAP-2, resulting in cisplatin resistance. Cisplatin 232-241 interleukin 6 Homo sapiens 202-206 20958132-6 2011 RESULTS: When it was acupunctured at the Ermen acupoint (triple energizer meridian 21) after an administration of cisplatin, PBS-pharmaceutical acupuncture significantly suppressed interleukin (IL)-6 production and caspase-3 activation induced by cisplatin in the cochlea. Cisplatin 114-123 interleukin 6 Homo sapiens 181-199 21273582-4 2011 The sensitivity of IL-6 transfectants to cisplatin was evaluated using a WST-8 assay and cell-cycle analysis. Cisplatin 41-50 interleukin 6 Homo sapiens 19-23 21273582-6 2011 IL-6 transfectants showed significantly reduced sensitivity to cisplatin compared to control transfectants. Cisplatin 63-72 interleukin 6 Homo sapiens 0-4 21273582-7 2011 In addition, the reduced cisplatin sensitivity of IL-6 transfectants was restored by pretreatment with IL-6-specific siRNA. Cisplatin 25-34 interleukin 6 Homo sapiens 50-54 21273582-7 2011 In addition, the reduced cisplatin sensitivity of IL-6 transfectants was restored by pretreatment with IL-6-specific siRNA. Cisplatin 25-34 interleukin 6 Homo sapiens 103-107 21273582-8 2011 These results suggest that intracellular IL-6 expression in tumor cells may acts as a resistance factor against cisplatin-based treatments for esophageal cancer. Cisplatin 112-121 interleukin 6 Homo sapiens 41-45 20236757-0 2010 Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cisplatin 46-55 interleukin 6 Homo sapiens 24-37 20236757-3 2010 Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs. Cisplatin 187-196 interleukin 6 Homo sapiens 99-103 20236757-3 2010 Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs. Cisplatin 187-196 interleukin 6 Homo sapiens 120-124 20236757-3 2010 Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs. Cisplatin 187-196 interleukin 6 Homo sapiens 120-124 20236757-3 2010 Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs. Cisplatin 187-196 interleukin 6 Homo sapiens 120-124 20236757-3 2010 Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs. Cisplatin 187-196 interleukin 6 Homo sapiens 120-124 20236757-3 2010 Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs. Cisplatin 187-196 interleukin 6 Homo sapiens 120-124 20236757-3 2010 Here we demonstrate that both exogenous (a relatively short period of treatment with recombination IL-6) and endogenous IL-6 (by transfecting with plasmid encoding for sense IL-6) induce cisplatin and paclitaxel resistance in non-IL-6-expressing A2780 cells, while deleting of endogenous IL-6 expression in IL-6-overexpressing SKOV3 cells (by transfecting with plasmid encoding for antisense IL-6) promotes the sensitivity of these cells to anticancer drugs. Cisplatin 187-196 interleukin 6 Homo sapiens 120-124 17516123-2 2007 In this study, we demonstrate that cisplatin increased the early immediate release and de novo synthesis of proinflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6, through the activation of ERK and NF-kappaB in HEI-OC1 cells, which are conditionally immortalized cochlear cells that express hair cell markers. Cisplatin 35-44 interleukin 6 Homo sapiens 170-174 20682658-0 2010 Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma. Cisplatin 0-9 interleukin 6 Homo sapiens 95-108 20682658-7 2010 Preliminary functional assessment of a gene, interleukin-6 (IL-6), highly upregulated in cisplatin-treated cells was carried out using clonogenicity and tumorigenicity assays. Cisplatin 89-98 interleukin 6 Homo sapiens 45-58 20682658-7 2010 Preliminary functional assessment of a gene, interleukin-6 (IL-6), highly upregulated in cisplatin-treated cells was carried out using clonogenicity and tumorigenicity assays. Cisplatin 89-98 interleukin 6 Homo sapiens 60-64 20682658-8 2010 We show that cisplatin-induced IL-6 expression can contribute to the increase in tumorigenic potential of head and neck cancer cells but does not contribute to cisplatin resistance. Cisplatin 13-22 interleukin 6 Homo sapiens 31-35 20682658-9 2010 Finally, through clonal analysis, we show that cisplatin-induced IL-6 expression and cisplatin-induced tumorigenicity are stochastically derived. Cisplatin 47-56 interleukin 6 Homo sapiens 65-69 20682658-10 2010 We report that cisplatin treatment of head and neck cancer cells results in a transient accumulation of cisplatin-resistant, small, and IL-6-positive cells that are highly tumorigenic. Cisplatin 15-24 interleukin 6 Homo sapiens 136-140 20942931-11 2010 Urine IL-6 did not significantly increase in pre-renal azotemia but did increase in ischemic and cisplatin AKI. Cisplatin 97-106 interleukin 6 Homo sapiens 6-10 18697197-4 2008 Treatment of tumor cells with doxorubicin and cisplatin resulted in a substantial increase in the production of IL-6, CXCL8, CCL2, CCL5, BFGF, G-CSF and VEGF. Cisplatin 46-55 interleukin 6 Homo sapiens 112-116 12729367-4 2003 It has been hypothesized that the link between cisplatin treatment and FMF attacks lies in an increased production of serotonin, IL-6, IL-1, IL-8 and TNF-alpha. Cisplatin 47-56 interleukin 6 Homo sapiens 129-133 17266043-5 2007 We showed that pro-inflammatory mediators including interleukin-6 (IL-6) could induce AKR1C1/1C2 expression in NSCLC cells and increase cellular resistance to cisplatin and adriamycin. Cisplatin 159-168 interleukin 6 Homo sapiens 52-65 17266043-5 2007 We showed that pro-inflammatory mediators including interleukin-6 (IL-6) could induce AKR1C1/1C2 expression in NSCLC cells and increase cellular resistance to cisplatin and adriamycin. Cisplatin 159-168 interleukin 6 Homo sapiens 67-71 16525642-8 2006 The combination of DHMEQ with cisplatin produced unexpected significant decrease in c-IAP-2 and Bcl-XS mRNAs as well as additive decrease (IL-6, NAIP and, after 16 h, Bcl-XL) or increase (XIAP at 8 h) in gene expression. Cisplatin 30-39 interleukin 6 Homo sapiens 139-143 12447990-3 2003 High serum levels of certain cytokines, for example interleukin-6 (IL-6), have been associated with poor prognosis and cisplatin resistance in various forms of cancer. Cisplatin 119-128 interleukin 6 Homo sapiens 52-65 12447990-3 2003 High serum levels of certain cytokines, for example interleukin-6 (IL-6), have been associated with poor prognosis and cisplatin resistance in various forms of cancer. Cisplatin 119-128 interleukin 6 Homo sapiens 67-71 12447990-7 2003 Curcumin inhibited the production of IL-6 in this cell suggesting that one of the mechanisms for synergy between cisplatin and curcumin was by reducing the autologous production of IL-6. Cisplatin 113-122 interleukin 6 Homo sapiens 37-41 12447990-7 2003 Curcumin inhibited the production of IL-6 in this cell suggesting that one of the mechanisms for synergy between cisplatin and curcumin was by reducing the autologous production of IL-6. Cisplatin 113-122 interleukin 6 Homo sapiens 181-185 10067009-1 1999 OBJECTIVE: To study whether interleukin-6 (IL-6) changes the expression of the anti-apoptic Bcl-2 protein in the prevention of cis-diaminedichloroplatinum (II) (CDDP)-induced apoptosis of human ovarian cancer cells. Cisplatin 127-159 interleukin 6 Homo sapiens 28-41 11942326-4 2002 Here we demonstrate that cisplatin (CDDP) and etoposide (VP-16) induce nuclear translocation of NF-kappaB in prostate cancer cell lines, followed by secretion of IL-6. Cisplatin 25-34 interleukin 6 Homo sapiens 162-166 11942326-4 2002 Here we demonstrate that cisplatin (CDDP) and etoposide (VP-16) induce nuclear translocation of NF-kappaB in prostate cancer cell lines, followed by secretion of IL-6. Cisplatin 36-40 interleukin 6 Homo sapiens 162-166 11885806-2 2002 Our study was designed to determine whether heat shock and drugs like cisplatin, etoposide and quercetin have an effect on the expression of heat shock protein 27 in tumour cells such as: HeLa (cervical cancer), Hep-2 (larynx cancer), A549 (lung cancer) and also in normal human skin fibroblasts (HSF) cultured in two-dimensional (2D) and three-dimensional (3D) conditions. Cisplatin 70-79 interleukin 6 Homo sapiens 297-300 12476615-2 2002 Our study was designed to determine whether heat shock and drugs like cisplatin, etoposide and quercetin influence the expression of heat shock protein 72 in tumour cells: HeLa (cervical cancer), Hep-2 (larynx cancer), A549 (lung cancer) and normal human skin fibroblasts (HSF). Cisplatin 70-79 interleukin 6 Homo sapiens 273-276 11593385-10 2001 Finally, overexpression of IL-6 in C33A cells caused a markable resistance to apoptosis induced by doxorubicin or cisplatin. Cisplatin 114-123 interleukin 6 Homo sapiens 27-31 10403520-10 1999 Our findings suggest that increased GSH biosynthesis in CDDP-resistant cancer cells may be involved in the attenuation of HSF activation by CdCl2. Cisplatin 56-60 interleukin 6 Homo sapiens 122-125 10067009-1 1999 OBJECTIVE: To study whether interleukin-6 (IL-6) changes the expression of the anti-apoptic Bcl-2 protein in the prevention of cis-diaminedichloroplatinum (II) (CDDP)-induced apoptosis of human ovarian cancer cells. Cisplatin 161-165 interleukin 6 Homo sapiens 43-47 10366426-5 1999 The results show that cis-diamminedichloroplatinum (CDDP) resistance was overcome by treatment with nontoxic doses of CDDP in combination with anti-IL-6 mAb. Cisplatin 22-50 interleukin 6 Homo sapiens 148-152 10366426-5 1999 The results show that cis-diamminedichloroplatinum (CDDP) resistance was overcome by treatment with nontoxic doses of CDDP in combination with anti-IL-6 mAb. Cisplatin 52-56 interleukin 6 Homo sapiens 148-152 10366426-8 1999 The current studies show that anti-IL-6 mAb sensitized CDDP-resistant K562 cells to CDDP by induction of apoptotic death and the reduction of glutathione levels might be implicated in the enhanced cytotoxicity observed. Cisplatin 55-59 interleukin 6 Homo sapiens 35-39 10366426-8 1999 The current studies show that anti-IL-6 mAb sensitized CDDP-resistant K562 cells to CDDP by induction of apoptotic death and the reduction of glutathione levels might be implicated in the enhanced cytotoxicity observed. Cisplatin 84-88 interleukin 6 Homo sapiens 35-39 10365139-1 1999 BACKGROUND: Interleukin (IL)-6 can suppress the cisplatin-induced induction of apoptosis in renal cell carcinoma (RCC) in vitro. Cisplatin 48-57 interleukin 6 Homo sapiens 12-30 10067009-7 1999 CONCLUSION: CDDP-induced apoptosis was negatively controlled by IL-6. Cisplatin 12-16 interleukin 6 Homo sapiens 64-68 10067009-1 1999 OBJECTIVE: To study whether interleukin-6 (IL-6) changes the expression of the anti-apoptic Bcl-2 protein in the prevention of cis-diaminedichloroplatinum (II) (CDDP)-induced apoptosis of human ovarian cancer cells. Cisplatin 127-159 interleukin 6 Homo sapiens 43-47 10067009-1 1999 OBJECTIVE: To study whether interleukin-6 (IL-6) changes the expression of the anti-apoptic Bcl-2 protein in the prevention of cis-diaminedichloroplatinum (II) (CDDP)-induced apoptosis of human ovarian cancer cells. Cisplatin 161-165 interleukin 6 Homo sapiens 28-41 9921985-0 1999 Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cisplatin 160-169 interleukin 6 Homo sapiens 55-68 9921985-4 1999 RESULTS: Both endogenous and exogenous IL-6 and exogenous OM up-regulated cell growth and enhanced resistance of PC-3 tumor cells to both etoposide and cisplatin. Cisplatin 152-161 interleukin 6 Homo sapiens 39-43 9875677-3 1998 The cultivation of human peripheral blood mononuclear cells (PBMC) in the presence of cisplatin (0-1.0 microg/ml) or 5-FU (0-5.0 microg/ml) resulted in the significant augmentation of natural killer (NK) and lymphokine-activated killer (LAK) cell activities as well as generation of interferon (IFN) gamma, tumor necrosis factor (TNF) alpha, beta interleukin(IL)-1beta, IL-6 and IL-12 in vitro. Cisplatin 86-95 interleukin 6 Homo sapiens 370-374 9738983-8 1998 Platinum compounds induced cytokine production in human EC: cisplatin most prominently induced the release of IL-1 and IL-6, and TRK-710 had the greatest ability to induce the release of GM-CSF. Cisplatin 60-69 interleukin 6 Homo sapiens 119-123 9538169-6 1998 These data suggest that NSCLC patients with high levels of IL-6 have a worse clinical outcome and may manifest resistance to cisplatin chemotherapy. Cisplatin 125-134 interleukin 6 Homo sapiens 59-63